Opportunity ContactEnikő Koppány, Business Development ManagerSzeged, Hungary University of Szeged Website Pharmalicensing.com The WYKYW pentapeptide is an endocytosis routing sequence for cell delivery of therapeutic macromolecules at therapeutically relevant nanomolar concentrations and
Both ABSOLVE and ABSCENT have been evaluated in the clinic and have been more effective / better tolerated than other obesity therapeutics.
Average weight loss is 10 lbs. during the first month’s use (observed range = 4 lbs. to 15 lbs.) and 2 lbs. to 10 lbs. per month thereafter.
ABSOLVE’s APIs are both components of other diet medicines.